Asahi Kasei Corporation (AHKSF)
| Market Cap | 14.23B +59.0% |
| Revenue (ttm) | 19.34B +1.2% |
| Net Income | 998.67M +17.6% |
| EPS | 0.74 +19.4% |
| Shares Out | n/a |
| PE Ratio | 14.25 |
| Forward PE | n/a |
| Dividend | 0.26 (2.72%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 11,591 |
| Average Volume | 1,509 |
| Open | 9.59 |
| Previous Close | n/a |
| Day's Range | 9.59 - 9.59 |
| 52-Week Range | 6.55 - 11.84 |
| Beta | 0.63 |
| RSI | 48.77 |
| Earnings Date | May 12, 2026 |
About Asahi Kasei
Asahi Kasei Corporation engages in material, homes, healthcare businesses. The company offers Pimel photosensitive polyimide/PBO precursor, a liquid photosensitive material for buffer coating and packaging applications; Sunfort dry film photoresist to form circuit patterns on printed wiring boards; Novacure, a latent curing agent for epoxy resin with storage stability; glass fabric for printed circuit boards; plastic optical fiber; suede products under the Dinamica name; Microza UF and MF industrial membranes and systems; Aciplex membranes, pro... [Read more]
Financial Performance
In fiscal year 2026, Asahi Kasei's revenue was 3.07 trillion, an increase of 1.22% compared to the previous year's 3.04 trillion. Earnings were 158.79 billion, an increase of 17.63%.
Financial numbers in JPY Financial StatementsNews
Asahi Kasei Optimizes Material Portfolio Through Supply Realignment by FY2030
TOKYO--(BUSINESS WIRE)--Asahi Kasei, a diversified global company, has announced plans to streamline operations at its Mizushima Works by fiscal 2030.
Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy
TOKYO--(BUSINESS WIRE)--Asahi Kasei has announced the successful completion of its acquisition of Aicuris Anti-infective Cures AG (Aicuris).
Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune Diseases
TOKYO--(BUSINESS WIRE)--Asahi Kasei announced the initiation of a Phase I clinical trial for AK1940, a novel peptide-based investigational compound.
Chevron Technology Ventures, Asahi Kasei Invest in Heavy-Industry Robotics Company KEWAZO
MUNICH & HOUSTON--(BUSINESS WIRE)--KEWAZO, the robotics company transforming heavy industry worldwide, today announced a new funding round backed by Chevron Technology Ventures, Asahi Kasei, Benson Ca...
Asahi Kasei Begins Installation of Containerized Alkaline-Water Electrolyzer at Finland's First Commercial Hydrogen Refueling Station
TOKYO--(BUSINESS WIRE)--Asahi Kasei has started the installation of an Aqualyzer™-C3 at Finland's first commercial hydrogen refueling station in Jyväskylä.
Asahi Kasei Strengthens Global Pharmaceutical Platform with the Acquisition of Aicuris
CHELMSFORD, Mass. & TOKYO--(BUSINESS WIRE)--Asahi Kasei announced it has entered into a definitive agreement to acquire all issued shares of Aicuris Anti-infective Cures AG.
Asahi Kasei to Acquire Aicuris to Accelerate Growth in Severe Infectious Diseases
Wuppertal, Germany, February 26, 2026 - Aicuris Anti-infective Cures AG (“Aicuris”) today announced that it has entered into a definitive agreement under which Asahi Kasei, through its wholly owned U...
Asahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for Novel Lead Compounds
TOKYO--(BUSINESS WIRE)--Asahi Kasei Pharma announced an exclusive global license agreement regarding novel lead compounds for a single target with Alchemedicine.
Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refractory Diseases
TOKYO--(BUSINESS WIRE)--Asahi Kasei Pharma in collaboration with Alchemedicine has announced that AK1960 has advanced to a Phase I clinical study.
Asahi Kasei Develops PFAS-Free PA66 Offering Low-Friction and High-Load Performance
DUESSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei announced the development of a new PFAS-free polyamide (PA) engineered specifically for demanding low-friction applications.
ZOLL Strengthens Growth Trajectory for Asahi Kasei's Healthcare Sector with U.S. Launch of the Next-Generation LifeVest® WCD and Rollout of the Most Comfortable LifeVest Garment Ever, Reinforcing Position as Leader in WCD Category
CHELMSFORD, Mass. & TOKYO--(BUSINESS WIRE)--Asahi Kasei announced that ZOLL® Medical has launched the next-generation LifeVest® wearable cardioverter defibrillator (WCD) in the U.S.
Asahi Kasei Pharma to Relocate Global R&D Hub to Shonan iPark
TOKYO--(BUSINESS WIRE)--Asahi Kasei Pharma Corporation has announced plans to relocate its R&D hub from Izunokuni City, Shizuoka Prefecture to Shonan Health Innovation Park.
Asahi Kasei Microdevices and Aizip Deliver Transformative AI-Enhanced Sensing Solutions
TOKYO--(BUSINESS WIRE)--Asahi Kasei Microdevices (AKM) and Aizip have partnered to showcase two innovations in AI-enhanced sensing.
Asahi Kasei Receives 2025 TSMC Excellent Performance Award in Recognition of Its PIMEL™ Photosensitive Dielectric for Advanced Packaging Material
TOKYO--(BUSINESS WIRE)--Asahi Kasei received a 2025 TSMC Excellent Performance Award for “Excellent Technology Development and Production Support.".
Asahi Kasei Strengthens Long-Term Profitability by Phasing Out HMD Production as Part of Structural Reform
TOKYO--(BUSINESS WIRE)--Asahi Kasei will discontinue production of hexamethylene diamine (HMD) as part of its ongoing portfolio optimization.
Asahi Kasei Accelerates Portfolio Transformation with Divestiture of Daramic Lead Battery Separator Business
TOKYO--(BUSINESS WIRE)--Asahi Kasei announces its strategic divestiture of Daramic, a lead battery separator business to Kingswood Capital Management, LP.
SENSIL® by NILIT and ROICA™ by Asahi Kasei Collaborate to Reduce Apparel's Footprint
MUNICH--(BUSINESS WIRE)-- #ISPO--Rapidly transforming apparel into a lower-carbon industry requires collaboration, innovation, and creativity. In this spirit, SENSIL® by NILIT and ROICA™ by Asahi Kase...
Asahi Kasei Advance and Teijin Frontier to Integrate Businesses for Sustainable Growth
TOKYO--(BUSINESS WIRE)--Asahi Kasei and Teijin have entered into an agreement to implement an absorption-type merger concerning Asahi Kasei Advance.
Asahi Kasei Wins BioTech Breakthrough Award for Planova™ FG1 Filter
CHELMSFORD, Mass. & TOKYO--(BUSINESS WIRE)--Asahi Kasei has earned top honors in the 2025 BioTech Breakthrough Awards, winning the Biomanufacturing Innovation of the Year for its Planova™ filter.
Asahi Kasei Microdevices Showcases AgeTech and PetTech Solutions Combining Privacy and Convenience at CES® 2026
TOKYO--(BUSINESS WIRE)--Asahi Kasei Microdevices Corporation (AKM) will showcase its latest sensing technologies for the growing AgeTech and PetTech markets at CES® 2026.
Asahi Kasei Licenses Novel Electrolyte Technology to EAS Batteries for the Market Launch of an Ultra-High-Power Cell
DUESSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei and EAS Batteries signed a license agreement for the use of Asahi Kasei's acetonitrile-containing electrolyte technology.
Nefecon Included in the Updated KDIGO Clinical Practice Guideline, Strengthening Asahi Kasei's Position in IgA Nephropathy Treatment
CHELMSFORD, Mass. & TOKYO--(BUSINESS WIRE)--2025 KDIGO Guideline suggests treatment with Nefecon should be considered in the majority of patients at risk of progressive loss of kidney function.
Asahi Kasei Expanding Capacity to Manufacture System Components for Clean Hydrogen
TOKYO--(BUSINESS WIRE)--Asahi Kasei has announced the official approval of new facilities at its Kawasaki Works to manufacture electrolysis system components.
Asahi Kasei Expands Healthcare Materials Portfolio with Sonanos™ Next-Generation Excipients
TOKYO--(BUSINESS WIRE)--Asahi Kasei announced the launch of two new specialty grades in its Sonanos portfolio.
Asahi Kasei Elevates Critical Care Solutions with FDA Approval of ZOLL's Zenix Monitor/Defibrillator
CHELMSFORD, Mass.--(BUSINESS WIRE)--Asahi Kasei has advanced its suite of critical care products through premarket approval by the FDA for ZOLL's Zenix® monitor/defibrillator.